Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

Hermine I. Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, Unknown

Open source

DOI: 10.1002/art.70274
Published: 2026-08-25
Container: Arthritis & Rheumatology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/art.70274,
  title = {Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study},
  author = {Hermine I. Brunner and Lyudmila Grebenkina and Irina Nikishina and Ekaterina Alexeeva and Vyacheslav Chasnyk and Carlos Abud‐Mendoza and Nadina Rubio‐Pérez and Heinrike Schmeling and María del Rocio Maldonado‐Velázquez and Diane Brown and Andrew Zeft and Esi Morgan and C. Egla Rabinovich and Daniel Kingsbury and Hulya Bukulmez and Beth Gottlieb and Thomas Griffin and Lisa Imundo and Stacey Tarvin and Earl Silverman and Laura Shaughnessy and Saori Shimizu and Paulette Williams and Rocío Lledó‐García and Gauri Utturkar and Baran Ufuktepe and Alberto Martini and Daniel J. Lovell and Nicolino Ruperto and Unknown},
  year = {2026},
  journal = {Arthritis \&amp; Rheumatology},
  doi = {10.1002/art.70274},
  url = {https://doi.org/10.1002/art.70274}
}

RIS

TY  - JOUR
TI  - Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study
AU  - Hermine I. Brunner
AU  - Lyudmila Grebenkina
AU  - Irina Nikishina
AU  - Ekaterina Alexeeva
AU  - Vyacheslav Chasnyk
AU  - Carlos Abud‐Mendoza
AU  - Nadina Rubio‐Pérez
AU  - Heinrike Schmeling
AU  - María del Rocio Maldonado‐Velázquez
AU  - Diane Brown
AU  - Andrew Zeft
AU  - Esi Morgan
AU  - C. Egla Rabinovich
AU  - Daniel Kingsbury
AU  - Hulya Bukulmez
AU  - Beth Gottlieb
AU  - Thomas Griffin
AU  - Lisa Imundo
AU  - Stacey Tarvin
AU  - Earl Silverman
AU  - Laura Shaughnessy
AU  - Saori Shimizu
AU  - Paulette Williams
AU  - Rocío Lledó‐García
AU  - Gauri Utturkar
AU  - Baran Ufuktepe
AU  - Alberto Martini
AU  - Daniel J. Lovell
AU  - Nicolino Ruperto
AU  - Unknown
PY  - 2026
JO  - Arthritis &amp; Rheumatology
DO  - 10.1002/art.70274
UR  - https://doi.org/10.1002/art.70274
ER  -

APA

Brunner, H. I., Grebenkina, L., Nikishina, I., Alexeeva, E., Chasnyk, V., Abud‐Mendoza, C., Rubio‐Pérez, N., Schmeling, H., Maldonado‐Velázquez, M. D. R., Brown, D., Zeft, A., Morgan, E., Rabinovich, C. E., Kingsbury, D., Bukulmez, H., Gottlieb, B., Griffin, T., Imundo, L., Tarvin, S., Silverman, E., Shaughnessy, L., Shimizu, S., Williams, P., Lledó‐García, R., Utturkar, G., Ufuktepe, B., Martini, A., Lovell, D. J., Ruperto, N., & Unknown (2026). Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.70274

Source records

crossref · retrieved 2026-09-26T18:47:05.358Z